Stem-like tumor-initiating cells isolated from IL13R?2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.
Ontology highlight
ABSTRACT: To evaluate IL13R?2 as an immunotherapeutic target for eliminating glioma stem-like cancer initiating cells (GSC) of high-grade gliomas, with particular focus on the potential of genetically engineered IL13R?2-specific primary human CD8(+) CTLs (IL13-zetakine(+) CTL) to target this therapeutically resistant glioma subpopulation.A panel of low-passage GSC tumor sphere (TS) and serum-differentiated glioma lines were expanded from patient glioblastoma specimens. These glioblastoma lines were evaluated for expression of IL13R?2 and for susceptibility to IL13-zetakine(+) CTL-mediated killing in vitro and in vivo.We observed that although glioma IL13R?2 expression varies between patients, for IL13R?2(pos) cases this antigen was detected on both GSCs and more differentiated tumor cell populations. IL13-zetakine(+) CTL were capable of efficient recognition and killing of both IL13R?2(pos) GSCs and IL13R?2(pos) differentiated cells in vitro, as well as eliminating glioma-initiating activity in an orthotopic mouse tumor model. Furthermore, intracranial administration of IL13-zetakine(+) CTL displayed robust antitumor activity against established IL13R?2(pos) GSC TS-initiated orthotopic tumors in mice.Within IL13R?2 expressing high-grade gliomas, this receptor is expressed by GSCs and differentiated tumor populations, rendering both targetable by IL13-zetakine(+) CTLs. Thus, our results support the potential usefullness of IL13R?2-directed immunotherapeutic approaches for eradicating therapeutically resistant GSC populations.
SUBMITTER: Brown CE
PROVIDER: S-EPMC3578382 | biostudies-literature | 2012 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA